Key result
An effect compartment model adequately captured the pharmacodynamics of intravenous dabigatran for activated clotting and thromboelastometric reaction times in rabbits, with a short equilibration half-time (<2 min).
Why the study?
Dabigatran has potential utility during cardiopulmonary bypass in children and adults, but its pharmacokinetic-pharmacodynamic relationship needed investigation in an intact animal model.
Comparison
Intravenous dabigatran 15 mg.kg −1
Design
Preclinical pharmacokinetic-pharmacodynamic animal study
Follow-up
420 min
Authors
Loading...
Animal data support dabigatran PK-PD modeling; leaves open translation to human cardiopulmonary bypass.
Intravenous dabigatran demonstrates a predictable pharmacokinetic-pharmacodynamic relationship with a short equilibration half-time in a rabbit model, providing data to inform future preclinical studies for cardiopulmonary bypass.
Eaton et al. (2022) studied Pharmacokinetic-pharmacodynamic modeling of dabigatran (n=10). Intravenous dabigatran was evaluated on Pharmacokinetic and pharmacodynamic parameters (activated clotting time and thromboelastometric reaction time). An effect compartment model adequately captured the pharmacodynamics of intravenous dabigatran for activated clotting and thromboelastometric reaction times in rabbits, with a short equilibration half-time (<2 min).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: